Aduhelm, a drug that received accelerated approval from the FDA for Alzheimer’s treatment, has shown success in early trials. Now researchers are working to find a way to deliver more of the drug to the brain to boost its effectiveness, according to the study published Jan. 4 in the New England Journal of Medicine.
Read the full post on Becker's Hospital Review - Healthcare News
